Data from the REDEFINE-1 trial (NCT05567796) were recently presented in Türkiye, assessing Novo Nordisk's CagriSema in adults with obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results